SB/Block Deal Brings Small Rx Line, OTC Options To Glaxo Merger
Executive Summary
SmithKline Beecham's acquisition of Block Drugs solidifies SB's number three position in the U.S. toothpaste market - and may increase the options for handling the consumer products business after the Glaxo/SmithKline merger.